http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3668873-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d78e03cc1e994a21bd7dace1921ad8ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45d648d3f832e39aca2b2d8904156099 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f7920b13c87bcdc8242fc19bdf4358b |
| publicationDate | 2020-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3668873-A1 |
| titleOfInvention | Imidazo[1,2-a]imidazol-2-one derivatives for the treatment of diseases such as parkinson's disease |
| abstract | The present invention relates to compounds of formula I wherein L is a bond, a triple bond, -C (O) NH- or -NHC (O) -; R1 represents a phenyl or a five or six membered heteroaryl group, optionally substituted by lower alkyl, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R2 is fluoro; R3 is fluoro or chloro; R4 is hydrogen, lower alkyl, halogen, hydroxy-substituted lower alkyl, S (O) 2CH3, or is a five- or six-membered heteroaryl group or a heterocycloalkyl group, which are optionally substituted by lower alkyl, hydroxy or = O; R5 and R6 are both methyl and the dotted line is a bond, or R5 and R6 are both methyl and the dotted line is nothing, or one of R5 and R6 is hydrogen and the other is a methyl, and the dotted line is nothing; or a pharmaceutically acceptable salt or acid addition salt, all possible tautomeric forms, a racemic mixture, or its corresponding enantiomer and / or optical isomer and / or stereoisomer. The compounds can be used for the treatment of Parkinson's disease, anxiety, vomiting, obsessive-compulsive disorder, autism, neuroprotection, cancer, depression and type 2 diabetes. |
| priorityDate | 2017-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.